Shares of Bruker Co. (NASDAQ:BRKR) have been given a consensus recommendation of “Hold” by the eight ratings firms that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $35.80.

Several brokerages have issued reports on BRKR. BTIG Research reiterated a “buy” rating and issued a $44.00 price target (up from $42.00) on shares of Bruker in a research note on Tuesday, February 12th. Zacks Investment Research upgraded shares of Bruker from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a research note on Tuesday, January 29th. ValuEngine upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 15th. BidaskClub upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Friday, January 11th. Finally, Needham & Company LLC started coverage on shares of Bruker in a research note on Wednesday, January 2nd. They set a “strong-buy” rating and a $39.00 price objective on the stock.

BRKR stock traded up $0.70 during midday trading on Thursday, hitting $39.91. The company’s stock had a trading volume of 439,248 shares, compared to its average volume of 610,293. The company has a current ratio of 2.18, a quick ratio of 1.33 and a debt-to-equity ratio of 0.36. Bruker has a twelve month low of $26.10 and a twelve month high of $39.83. The firm has a market capitalization of $6.15 billion, a P/E ratio of 28.51, a PEG ratio of 2.15 and a beta of 1.47.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Monday, February 11th. The medical research company reported $0.54 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.54. Bruker had a net margin of 9.48% and a return on equity of 26.36%. The firm had revenue of $553.60 million for the quarter, compared to analyst estimates of $544.53 million. As a group, equities research analysts forecast that Bruker will post 1.57 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 22nd. Stockholders of record on Tuesday, March 5th will be paid a dividend of $0.04 per share. The ex-dividend date is Monday, March 4th. This represents a $0.16 annualized dividend and a dividend yield of 0.40%. Bruker’s dividend payout ratio is presently 11.43%.

Institutional investors have recently added to or reduced their stakes in the company. Chicago Equity Partners LLC boosted its holdings in shares of Bruker by 4.4% during the 4th quarter. Chicago Equity Partners LLC now owns 9,415 shares of the medical research company’s stock worth $280,000 after buying an additional 400 shares during the period. State Board of Administration of Florida Retirement System boosted its holdings in shares of Bruker by 0.4% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 144,802 shares of the medical research company’s stock worth $4,311,000 after buying an additional 510 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Bruker by 8.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,136 shares of the medical research company’s stock valued at $212,000 after purchasing an additional 550 shares during the period. Hanseatic Management Services Inc. boosted its holdings in Bruker by 52.0% in the 4th quarter. Hanseatic Management Services Inc. now owns 1,692 shares of the medical research company’s stock valued at $50,000 after purchasing an additional 579 shares during the period. Finally, Strs Ohio boosted its holdings in Bruker by 6.2% in the 4th quarter. Strs Ohio now owns 10,148 shares of the medical research company’s stock valued at $302,000 after purchasing an additional 591 shares during the period. Institutional investors own 67.97% of the company’s stock.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Read More: Why do companies pay special dividends?

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.